Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0QY3R
|
||||
| Former ID |
DNC006563
|
||||
| Drug Name |
Cbz-Ile-t-ButylhomoGlu-Ala-LeuVSMe
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C35H56N4O9S
|
||||
| Canonical SMILES |
CCC(C)C(C(=O)NC(CCCC(=O)OC(C)(C)C)C(=O)NC(C)C(=O)NC(CC(<br />C)C)C=CS(=O)(=O)C)NC(=O)OCC1=CC=CC=C1
|
||||
| InChI |
1S/C35H56N4O9S/c1-10-24(4)30(39-34(44)47-22-26-15-12-11-13-16-26)33(43)38-28(17-14-18-29(40)48-35(6,7)8)32(42)36-25(5)31(41)37-27(21-23(2)3)19-20-49(9,45)46/h11-13,15-16,19-20,23-25,27-28,30H,10,14,17-18,21-22H2,1-9H3,(H,36,42)(H,37,41)(H,38,43)(H,39,44)/b20-19+/t24-,25-,27+,28-,30-/m0/s1
|
||||
| InChIKey |
JWIOGOVPAFUFAB-OKNAZKIESA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Cathepsin B | Target Info | Inhibitor | [1] | |
| Cathepsin S | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | Lysosome | ||||
| Antigen processing and presentationhsa04142:Lysosome | |||||
| Phagosome | |||||
| Antigen processing and presentation | |||||
| Tuberculosis | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| IL2 Signaling PathwayNetPath_22:Leptin Signaling Pathway | |||||
| IL2 Signaling Pathway | |||||
| Reactome | Collagen degradation | ||||
| Trafficking and processing of endosomal TLR | |||||
| Assembly of collagen fibrils and other multimeric structures | |||||
| MHC class II antigen presentationR-HSA-1236977:Endosomal/Vacuolar pathway | |||||
| Degradation of the extracellular matrix | |||||
| MHC class II antigen presentation | |||||
| WikiPathways | Class I MHC mediated antigen processing & presentation | ||||
| Trafficking and processing of endosomal TLR | |||||
| References | |||||
| REF 1 | J Med Chem. 2006 May 18;49(10):2953-68.Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.